Actualités

Boston Scientific stock has had a tough run over the past year, yet the valuation checks still lean supportive, setting up a clear tension between recent share price weakness and what the broader metrics suggest about value. Boston Scientific shares are down about 58.1% over the past year, which sharply resets expectations around what investors are willing to pay for the business. Upcoming earnings and progress integrating recent device acquisitions may support sentiment, while ongoing Class...

Recall driven attention on Boston Scientific stock Boston Scientific (BSX) is back in focus after a series of voluntary recalls for its CRE and CRE Pro Wireguided gastrointestinal devices, tied to potential sterile pouch breaches across widely distributed product lots. With more than 81,000 units cited in individual recall notices and a worldwide distribution footprint, the situation brings product quality controls, potential regulatory implications and timing before the upcoming earnings...

Boston Scientific (BSX) reached $43.19 at the closing of the latest trading day, reflecting a -1.33% change compared to its last close.

The market is offering a steep discount on this medical device maker, but the price tag comes with a story about slowing growth. Here’s how to read it.

The trade tech company says Cervo AI can speed up customs brokerage tasks as tariff and trade policies shift.

BSX faces Q2 results with growth expected in key businesses, but lowered full-year guidance, cost pressures and weak stock performance cloud the outlook.

Globus Medical, Inspire Medical Systems, and Penumbra show varied revenue growth and analyst ratings, offering medical device investors alternatives to traditional pharmaceutical stocks.

Intuitive Surgical shares fell about 10% after Q2 2026 revenue rose 19% but guidance for da Vinci procedure growth wasn't raised, pushing ISRG below its 200-week moving average.

The healthcare giant's stock jump was about more than an earnings beat, offering proof of a growth story broader and more resilient than you thought.

JNJ beats Q2 estimates and raises 2026 guidance, but shares fall as MedTech misses expectations. Find out what weighed on the unit and what's next.

This healthcare giant is forecasting a significant acceleration, but you are being asked to look past a slowdown in its biggest growth engine and other execution hurdles.

Abbott’s (ABT) latest financial disclosure reveals a significant strategic evolution that market participants often overlook amidst the focus on quarterly beats. The company is actively executing a structural pivot, shifting its capital allocation and growth dependency away from the volatile Nutrition segment toward high-margin, innovation-led MedTech and specialized diagnostics.

SpaceX, IBM and Boston Scientific fell to 52-week lows on Wednesday as Wall Street concerns and profit-taking sent the stocks lower.

Shareholders of Boston Scientific would probably like to forget the past six months even happened. The stock dropped 52.5% and now trades at $42.79. This was partly driven by its softer quarterly results and might have investors contemplating their next move.

With an upside potential of 62.55%, Boston Scientific Corporation (NYSE:BSX) is among the 12 Strong Buy Stocks with High Upside According to Analysts. On July 8, Needham analyst Mike Matson lowered the firm’s price target on Boston Scientific Corporation (NYSE:BSX) to $57 from $77 while maintaining a Buy rating on the shares. The adjustment followed management commentary […]

Boston Scientific recently initiated several voluntary Class II recalls of its CRE and CRE Pro Wireguided endoscopy devices worldwide due to potential sterile breaches in packaging, affecting tens of thousands of units across multiple size ranges. The recalls underscore the operational and regulatory risks inherent in Boston Scientific’s expanding minimally invasive device portfolio, especially as it integrates recent acquisitions and scales global distribution. We’ll now examine how these...

In the latest trading session, Boston Scientific (BSX) closed at $42.63, marking a -4.52% move from the previous day.

Intuitive Surgical heads into Q2 earnings with strong procedure momentum, da Vinci 5 adoption and expectations for another earnings beat despite margin pressures.

Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.

Boston Scientific Corporation (NYSE:BSX) is one of the 10 Best Stocks to Buy in 2026 According to Billionaire D.E. Shaw. Boston Scientific Corporation (NYSE:BSX) is one of the largest medical device companies in America. Its shares are down by 56% over the past year and by 52% year-to-date. Jefferies was out with a devastating note […]

The average brokerage recommendation (ABR) for Boston Scientific (BSX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

If you hold shares in this medical device maker, you are already carrying the full weight of a sizable potential swing that the market is pricing for the year ahead.

Johnson & Johnson expects U.S. physicians to perform the first procedures with the device this summer as it starts a phased commercial rollout.

Steve Cohen, head of Point72 Asset Management, dumped tech stocks and bought this unloved healthcare company.

Generate an immediate income that you keep regardless, plus the opportunity to buy the stock cheaper should its price fall far enough.

Boston Scientific stock moves after clinical results and index changes Boston Scientific (BSX) has come into focus after promising clinical results coincided with multiple index removals and fresh analyst commentary on its Watchman device franchise and utilization trends. Shares recently moved higher, supported by the clinical update and reports of insider buying, even as analysts highlighted slower Watchman growth and trimmed their expectations. At the same time, Boston Scientific was...

Boston Scientific (BSX) closed at $44.6 in the latest trading session, marking a -1.2% move from the prior day.

Boston Scientific Corporation (NYSE:BSX) is one of the best stocks to invest in according to Two Sigma Advisors with huge upside potential. On June 24, Jefferies analyst Matthew Taylor cut his price target on Boston Scientific Corporation (NYSE:BSX) to $67 from $100, while keeping a Buy rating on the stock. The analyst stated that a […]

Boston Scientific stock has fallen 56.5% over the past year, yet the valuation checks still lean toward the shares looking cheap relative to fundamentals and recent news has put a fresh spotlight on whether that gap is justified. The 56.5% one year share price decline raises the question of whether Boston Scientific is being priced for a much weaker outlook than its long term potential would suggest. On one side, the US$1.5b investment in MiRus and option to acquire its TAVR business may...